| The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. | |
| | |
MedLine Citation:
|
PMID: 18758126 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The existence of microalbuminuria (MAU) in patients with essential hypertension is a strong indicator of microvascular damage. Although endothelial dysfunction and increased vascular permeability both have a role in the development of MAU, its ethiopathogenesis in hypertensive patients is not yet clearly understood. Vascular endothelial growth factor (VEGF) is the most important regulator of pathological or physiological angiogenesis and it additionally leads to increased vascular permeability. This study aims to assess the relationship of serum VEGF levels to MAU in non-complicated, newly-diagnosed essential hypertensive patients (EHs). METHODS: This study included 30 newly-diagnosed EHs with MAU, 46 newly-diagnosed EHs without MAU and 46 healthy controls. None of the EHs had diabetes, renal impairment or atherosclerotic diseases. Serum VEGF levels were measured using the ELISA method. RESULTS: Serum levels of VEGF were significantly higher in EHs with MAU when compared with patients without MAU (225.15+/-109.34 pg/mL versus 166.78+/-114.35 pg/mL, p: 0.04) or controls (225.15+/-109.34 pg/mL versus 144.91+/-96.60 pg/mL, p: 0.007). On the other hand, no significant difference was observed between the non-MAU and control groups. In the univariate analysis, serum levels of VEGF, were positively correlated with systolic blood pressure (R: 0.253 p: 0.001), diastolic blood pressure (R: 0.162 p: 0.04), mean arterial pressure (R: 0.239 p: 0.002), creatinine clearance (R: 0.172 p: 0.04) and MAU (R: 0.338 p: 0.002). In the multiple linear regression analysis, VEGF levels were independently related to MAU (beta: 0.248, p: 0.02). CONCLUSION: VEGF levels are higher in EHs in the presence of MAU. These high values may be important in the early diagnosis of vascular damage in EHs. Additionally, VEGF may increase glomerular permeability and lead to MAU in EHs. |
| | |
Authors:
|
Fatma Ayerden Ebinç; Ebinç Haksun; Derici Boztepe Ulver; Eyüp Koç; Yasemin Erten; Kadriye Reis Altok; Musa Bali; Arinsoy Turgay; Sükrü Sindel |
Related Documents
:
|
10872556 - The 'adrenaline hypothesis' of hypertension revisited: evidence for adrenaline release ... 21418376 - Influence of maternal nutritional status on vascular function in the offspring. 8879896 - Effect of manidipine chloride on various aspects of endocrine function, including plasm... 12574096 - Lipid peroxidation is not increased in patients with untreated mild-to-moderate hyperte... 12236336 - The human nociceptive flexion reflex threshold is higher during systole than diastole. 6373696 - Cardiopulmonary effects of unilateral airway pressure changes in intact infant lambs. |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2008-09-01 |
Journal Detail:
|
Title: Internal medicine (Tokyo, Japan) Volume: 47 ISSN: 1349-7235 ISO Abbreviation: Intern. Med. Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-09-01 Completed Date: 2009-03-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9204241 Medline TA: Intern Med Country: Japan |
Other Details:
|
Languages: eng Pagination: 1511-6 Citation Subset: IM |
Affiliation:
|
Faculty of Medicine, Department of Nephrology, Gazi University. fayerdenebin@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Albuminuria / complications*, diagnosis, physiopathology* Endothelium, Vascular / pathology* Female Humans Hypertension / complications*, diagnosis, physiopathology* Male Middle Aged Vascular Diseases / complications, diagnosis, physiopathology Vascular Endothelial Growth Factor A / physiology* |
| Chemical | |
Reg. No./Substance:
|
0/Vascular Endothelial Growth Factor A |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chron...
Next Document: Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary sy...